Skip to main content
SpringerLink
Log in

Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Lamb HM, Goa KL. Management of patients with cystic fibrosis: defining the role of inhaled tobramycin. Dis Manage Health Outcomes 1999; 6(2): 93–108

    Article  Google Scholar 

  2. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®): a review of its use in the management of pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63(22): 2501–20

    Article  PubMed  CAS  Google Scholar 

  3. CHIRON Corporation. TOBI Prescribing Information. Emeryville (CA): CHIRON Corporation, 2001

    Google Scholar 

  4. Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls. Infect Dis Clin Pract 1998 Feb; 7(2): 66–79

    Article  Google Scholar 

  5. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999 Jan 7; 340(1): 23–30

    Article  PubMed  CAS  Google Scholar 

  6. Ramsey BW, Schaeffler B, Montgomery AB, et al. Survival and lung function during 2 years treatment with intermittent inhaled tobramycin in CF patients [abstract no. 237]. Neth J Med 1998; 54 Suppl. : S83–4

    Article  Google Scholar 

  7. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002 Sep; 20(3): 658–64

    Article  PubMed  CAS  Google Scholar 

  8. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999 May; 179(5): 1190–6

    Article  PubMed  CAS  Google Scholar 

  9. lies R, Legh-Smith J, Prevost T, et al. Economic evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cystic Fibrosis 2003; 2: 120–8

    Article  Google Scholar 

  10. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003 Mar; 167(6): 841–9

    Article  PubMed  Google Scholar 

  11. British National Formulary. No. 47. London: The Pharmaceutical Press, Mar 2004

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs Ther. Perspect 20, 1–4 (2004). https://doi.org/10.2165/00042310-200420090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420090-00001

Search

Navigation